Minerva Neurosciences Inc (NERV)
2.38
-0.02
(-0.83%)
USD |
NASDAQ |
May 02, 15:13
Minerva Neurosciences Total Assets (Quarterly): 56.90M for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 56.90M |
| September 30, 2023 | 63.13M |
| June 30, 2023 | 67.14M |
| March 31, 2023 | 51.59M |
| December 31, 2022 | 55.09M |
| September 30, 2022 | 59.76M |
| June 30, 2022 | 64.96M |
| March 31, 2022 | 70.62M |
| December 31, 2021 | 77.12M |
| September 30, 2021 | 97.56M |
| June 30, 2021 | 105.32M |
| March 31, 2021 | 111.83M |
| December 31, 2020 | 57.63M |
| September 30, 2020 | 65.22M |
| June 30, 2020 | 66.17M |
| March 31, 2020 | 68.79M |
| December 31, 2019 | 77.50M |
| September 30, 2019 | 110.81M |
| June 30, 2019 | 120.29M |
| March 31, 2019 | 129.80M |
| December 31, 2018 | 139.14M |
| Date | Value |
|---|---|
| September 30, 2018 | 150.53M |
| June 30, 2018 | 160.94M |
| March 31, 2018 | 174.47M |
| December 31, 2017 | 183.70M |
| September 30, 2017 | 193.51M |
| June 30, 2017 | 127.38M |
| March 31, 2017 | 135.31M |
| December 31, 2016 | 132.94M |
| September 30, 2016 | 141.72M |
| June 30, 2016 | 146.50M |
| March 31, 2016 | 94.43M |
| December 31, 2015 | 82.58M |
| September 30, 2015 | 89.32M |
| June 30, 2015 | 94.32M |
| March 31, 2015 | 101.85M |
| December 31, 2014 | 68.45M |
| September 30, 2014 | 73.33M |
| June 30, 2014 | 52.96M |
| March 31, 2014 | 53.14M |
| December 31, 2013 | 29.17M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
51.59M
Minimum
Mar 2023
120.29M
Maximum
Jun 2019
76.18M
Average
67.14M
Median
Jun 2023
Total Assets (Quarterly) Benchmarks
| Viking Therapeutics Inc | 967.52M |
| Janux Therapeutics Inc | 380.41M |
| ACADIA Pharmaceuticals Inc | 748.96M |
| Karyopharm Therapeutics Inc | 240.44M |
| Calidi Biotherapeutics Inc | 10.02M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 85.36M |
| Shareholders Equity (Quarterly) | -28.46M |